Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ESOC1 siRNA
- Development stage
- Preclinical
- Lead developer
- University of Tokyo
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
ESOC1 siRNA is a small interfering RNA designed to target and suppress the expression of the esophageal cancer-associated oncoprotein 1 (ESOC1), a SAM-dependent methyltransferase. ESOC1 is overexpressed in the majority of esophageal cancers and is associated with poor prognosis, while its expression is minimal in normal tissues except for the testis. By utilizing the RNA interference (RNAi) pathway, ESOC1 siRNA effectively inhibits the growth and survival of esophageal cancer cells. Research indicates that ESOC1's methyltransferase activity on small non-coding RNAs contributes to its oncogenic potential, making it a promising therapeutic target for esophageal cancer.
- Other names
- siRNA targeting ESOC1
02
Targets
Innate immune RNA sensorsESOC1 (Esophageal cancer-associated oncoprotein 1)
Beyond the preview
Go deeper on ESOC1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ESOC1 siRNA.